CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PDUFA Dates November 2026: 20 FDA Decisions

Updated November 17, 2026

These dates are public. The filterable calendar, alerts, exports and AI research are in the app — free account: the next 7 days and 3 companies you track. Plans →

20 FDA decisions (PDUFA target action dates) fall in November 2026: 18 with a confirmed day, 6 already decided. Next: Molgramostim (SVRA) on Nov 22. Each row shows the drug, company, indication, status and how firm the date is.

FDA decisions in November 2026
DateCompanyDrugIndicationEventStatusDateTrack
Nov 10NRXPPreservative-free Ketamine—PDUFAApprovedConfirmed · source
Nov 13MRKClesrovimabPrevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under 2 years of age at increased risk for severe RSV disease through their second RSV seasonPDUFAApprovedConfirmed · source
Nov 14SMMTIvonescimab InjectionEGFR-mutated non-squamous NSCLC after prior EGFR TKI therapyPDUFACRL / not approvedConfirmed · source
Nov 14BTAISublingual film containing DexmedetomidineAt-home acute treatment of agitation associated with bipolar disorders or schizophreniaPDUFAPendingConfirmed · source
Nov 14CYTKAficamten (CK-3773274)Obstructive hypertrophic cardiomyopathy (label update based on MAPLE-HCM)PDUFAPendingConfirmed · source
~NovemberREGNCemdisiranAnti-AChR antibody-positive generalized myasthenia gravisPDUFAPendingEstimated · source
~NovemberALNYcemdisiranGeneralized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positivePDUFAPendingEstimated · source
Nov 16MRKClesrovimabPrevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under 2 years of age at increased risk for severe RSV disease through their second RSV seasonPDUFAApprovedConfirmed · source
Nov 22SVRAMolgramostimAutoimmune pulmonary alveolar proteinosisPDUFAPendingConfirmed · source
Nov 22CAPRDeramiocel (CAP-1002)Duchenne muscular dystrophy (upper limb function)PDUFAPendingConfirmed · source
Nov 25SNYVenglustatType 3 Gaucher diseasePDUFAPendingConfirmed · source
Nov 27GSKNeladalkib (NVL-655)TKI pre-treated advanced ALK-positive NSCLCPDUFAPendingConfirmed · source
Nov 27RPRXneladalkibnon-small cell lung cancer (ALK-positive)PDUFAPendingConfirmed · source
Nov 27BBIOBBP-418Limb-girdle muscular dystrophy type 2I/R9PDUFAPendingConfirmed · source
Nov 27BBOTBBP-418—PDUFAPendingAI-detected · source
Nov 28PYPDD-PLEXPrevention of surgical site infections in abdominal colorectal surgeryPDUFAPendingConfirmed · source
Nov 30RHHBYGiredestrantAdjuvant ER-positive, HER2-negative stage I-III breast cancerPDUFAApprovedConfirmed · source
Nov 30ZLABpovetaciceptimmunoglobulin A nephropathy (IgAN)PDUFAPendingConfirmed · source
Nov 30VRTXPovetaciceptIgA nephropathyPDUFAPendingConfirmed · source
Nov 30RHHBYObinutuzumab/IntravenousPrimary membranous nephropathyPDUFAApprovedConfirmed · source
240
Total Catalysts
20
PDUFA Dates
100
Trial Results
175
Companies

Week 1Oct 26 - Nov 1(9 catalysts)

  • Nov 2026~SRRKApitegromab Phase 3 Est. Readout (ONYX)
  • Nov 2026~BMYKarXT Phase 3 Est. Readout (BALSAM-1)
  • Nov 1RDYOther - semaglutide
  • Nov 2026~GSKBelantamab mafodotin Phase 2 Est. Readout
  • Nov 2026~REGNDupilumab Phase 2 Est. Readout
  • Nov 2026~GILDSacituzumab Govitecan-Hziy plus bevacizumab Phase 2 Est. Readout
  • Nov 2026~CRBPCRB-601 monoclonal antibody Phase 2 Est. Readout
  • Nov 2026~ESALYLenvatinib Phase 2 Est. Readout
  • Nov 2026~PHVSIcatibant Phase 3 Est. Readout

Week 2Nov 2 - Nov 8(59 catalysts)

USNARegulatory
Past

USANA BiOmega Earns ConsumerLab Seal of Approval for Quality and Purity

Nov 3
00%
Source
TNYARegulatory
Past

Regulatory Decision - TN-401

Nov 4
✓PositiveSource
CRISRegulatory
Past

Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026

Nov 5
📊Data ReleasedSource
ELANRegulatory
Past

October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority

Nov 6
00%
Source
  • Nov 2INDVINDV M&A / Acquisition
  • Nov 2026~REGNFixed Dose Combination (FDC) cemiplimab+fianlimab Phase 2 Est. Readout
  • Nov 2SUPNSUPN M&A / Acquisition
  • Nov 2026~TLSAForalumab Nasal Phase 2 Est. Readout
  • Nov 2TOVXTOVX M&A / Acquisition
  • Nov 2BIAFBIAF — Stock Offering (424B5)
  • Nov 2KPTIAcquisition — Ayrmid Ltd. ($55M)
  • Nov 2026~ENLVAllocetra Phase 2 Est. Readout
  • Nov 2KVAUFKVAUF M&A / Acquisition
  • Nov 2026~RHHBYRisdiplam Phase 3 Est. Readout (MANATEE)
  • Nov 3CRDLStock Offering
  • Nov 3LONN.SWAcquisition — Merck KGaA
  • Nov 2026~TLSAForalumab Nasal Phase 2 Est. Readout
  • Nov 3MDWDMDWD — Stock Offering (424B5)
  • Nov 2026~SDZ.SWCYB704 Phase 3 Est. Readout
  • Nov 3RMTIAcquisition — Vantive Limited ($400M)
  • Nov 2026~NVSLOU064 (blinded) Phase 3 Est. Readout
  • Nov 2026~RYTMSetmelanotide Phase 2 Est. Readout
  • Nov 2026~REGNCemiplimab Phase 3 Est. Readout
  • Nov 4ANVSANVS — Stock Offering (424B5)
  • Nov 4WVEConference Presentation
  • Nov 4GNTAOther
  • Nov 4ARQTARQT — Stock Offering (424B5)
  • Nov 4BIVIBIVI — Stock Offering (424B5)
  • Nov 4DSGNDSGN — Stock Offering (424B5)
  • Nov 4QNRXQNRX — Stock Offering (424B5)
  • Nov 4LYELStock Offering — $80 million
  • Nov 5IMUXConference Presentation
  • Nov 5VYGRVYGR M&A / Acquisition
  • Nov 5IRONIRON — Stock Offering (424B5)
  • Nov 5ISPCISPC M&A / Acquisition
  • Nov 5DTILStock Offering — $79.4M (10.24M shares at $7.75, calculated; excludes any underwriter option)
  • Nov 5ANIPAcquisition — Egetis Therapeutics AB ($300M)
  • Nov 5OBIOOBIO — Stock Offering (424B5)
  • Nov 5INOINO — Stock Offering (424B5)
  • Nov 5FATEFATE — Stock Offering (424B5)
  • Nov 2026~TLSAForalumab Nasal Phase 2 Est. Readout
  • Nov 5AZNAcquisition — Rhythm Pharmaceuticals ($10B)
  • Nov 5DRTSOther - Alpha DaRT
  • Nov 2026~AZNAZD9750 Phase 2 Est. Readout
  • Nov 2026~IQVBedaquiline, pretomanid and TBD09 Phase 2 Est. Readout
  • Nov 2026~INCYparsaclisib + itacitinib Phase 2 Est. Readout
  • Nov 5AVTXAVTX — Stock Offering (424B5)
  • Nov 5NBIXConference Presentation
  • Nov 2026~PCVX31-valent pneumococcal conjugate vaccine Phase 3 Est. Readout
  • Nov 5IVAConference
  • Nov 5TECXTECX M&A / Acquisition
  • Nov 2026~NVSAAA617 Phase 2 Est. Readout
  • Nov 6RGENStock Offering
  • Nov 6ZBIOZBIO — Stock Offering (424B5)
  • Nov 6EVAXConference — EVX-01
  • Nov 6ACRVAcquisition — Aqilion AB
  • Nov 6JSPROther
  • Nov 6VSTMStock Offering
  • Nov 6ATYRATYR — Stock Offering (424B5)

Week 3Nov 9 - Nov 15(91 catalysts)

NRXPPDUFA
Past

FDA GDUFA Goal Date Preservative-free Ketamine

Preservative-free KetamineNDA
Nov 10
✓PositiveSEC
RIGLRegulatory
Past

Rigel to Present at the Jefferies Global Healthcare Conference in London

Nov 10
📊Data ReleasedSource
NRXPRegulatory
Past

Regulatory Decision - Preservative-Free Ketamine

Nov 10
✓PositiveSource
CRISRegulatory
Past

Curis Provides Third Quarter 2026 Business Update

Nov 12
📊Data ReleasedSource
XRTXRegulatory
Past

Regulatory Decision - XRx-101

Nov 13
✓PositiveSource
MRKPDUFA
Past

FDA PDUFA Date ENFLONSIA (clesrovimab)

ClesrovimabPhase 3

Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under 2 years of age at increased risk for severe RSV disease through their second RSV season

Nov 13
✓PositiveSEC
SMMTPDUFA
Past

FDA PDUFA Date ivonescimab

Ivonescimab InjectionPhase 3

EGFR-mutated non-squamous NSCLC after prior EGFR TKI therapy

Nov 14
✗NegativeSource
BTAIPDUFA
Past

FDA PDUFA Date Dexmedetomidine sublingual film (IGALMI)

Sublingual film containing DexmedetomidinePhase 2

At-home acute treatment of agitation associated with bipolar disorders or schizophrenia

Nov 14
00%
Source
CYTKPDUFA
Past

FDA PDUFA Date Aficamten (MYQORZO)

Aficamten (CK-3773274)Phase 3

Obstructive hypertrophic cardiomyopathy (label update based on MAPLE-HCM)

Nov 14
00%
Source
Aficamten (CK-3773274) FDA decision page →
REGNPDUFA
Nov '26

FDA PDUFA Date cemdisiran

CemdisiranPhase 3

Anti-AChR antibody-positive generalized myasthenia gravis

Nov 2026~
00%
Source
ALNYPDUFA
Nov '26

FDA PDUFA Date cemdisiran (priority)

cemdisiranNDA

Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive

Nov 2026~
00%
SEC
  • Nov 9MTRIAcquisition
  • Nov 9MNPRConference — ALXN1840
  • Nov 9JAGXJAGX — Stock Offering (424B5)
  • Nov 9ABEOABEO M&A / Acquisition
  • Nov 2026~TLSAForalumab Nasal Phase 2 Est. Readout
  • Nov 9HRTXAcquisition — CorMedix Therapeutics ($145M)
  • Nov 9CRMDAcquisition — Heron Therapeutics ($145M)
  • Nov 9ARGXAcquisition — Unnatural Products ($1.15B)
  • Nov 9CRLAcquisition — Frontage Holdings Corporation ($470M)
  • Nov 9NKTXConference Presentation - NKX019
  • Nov 9MDCXConference Presentation - CD228V
  • Nov 9HELPConference Presentation - HLP003
  • Nov 9PFEConference
  • Nov 10QNTMOther
  • Nov 10NXTCAcquisition — Avere Therapeutics, Inc. ($820M)
  • Nov 10EPRXStock Offering — US$125 million
  • Nov 10PEPGData Readout - PepGen's muscular dystrophy therapy
  • Nov 10STIMSTIM — Stock Offering (424B5)
  • Nov 2026~TLSAForalumab Nasal Phase 2 Est. Readout
  • Nov 10MXCTAcquisition — Akron Bio ($10.2M)
  • Nov 10PRMEPRME — Stock Offering (424B5)
  • Nov 10PACBPACB — Stock Offering (424B5)
  • Nov 10PEPGPEPG — Stock Offering (424B5)
  • Nov 11AMGNAMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
  • Nov 11PCRXAcquisition — Ingram Micro Holding Corp.
  • Nov 11SLXNOther - SIL204
  • Nov 2026~PGENPRGN-2009 plus Pembrolizumab Phase 2 Est. Readout
  • Nov 11RGNXConference Presentation
  • Nov 2026~EXELCabozantinib Phase 2 Est. Readout (CANOPY)
  • Nov 12VIRVIR — Stock Offering (424B5)
  • Nov 2026~PFEPF-07275315 Phase 2 Est. Readout
  • Nov 12PROFConference Presentation - TULSA-PRO
  • Nov 12PROKPROK — Stock Offering (424B5)
  • Nov 12AEMDAcquisition — North Immunology, Inc. ($6.5M)
  • Nov 12CADLCADL — Stock Offering (424B5)
  • Nov 13XBIOAcquisition — Santersus AG
  • Nov 13NTHIConference Presentation - NEO100
  • Nov 2026~ENLVAllocetra Phase 2 Est. Readout
  • Nov 13RZLTRZLT — Stock Offering (424B5)
  • Nov 13NNOXNNOX — Stock Offering (424B5)
  • Nov 13IBOAcquisition
  • Nov 2026~RHHBYInavolisib Phase 3 Est. Readout (INAVO121)
  • Nov 2026~REGNREGN7075 Phase 2 Est. Readout (COMBINE-EGFR-1)
  • Nov 13ABBVConference Presentation
  • Nov 2026~CGONCretostimogene Grenadenorepvec Phase 3 Est. Readout
  • Nov 2026~PFEPertuzumab Phase 2 Est. Readout (BRIDGET)
  • Nov 2026~ABBVUpadacitinib Phase 3 Est. Readout (Switch-Up)
  • Nov 2026~ALCApraclonidine Ophthalmic Solution, Unit Dose Preservative Free Phase 3 Est. Readout
  • Nov 2026~TYRATYRA-300 Phase 2 Est. Readout (SURF301)
  • Nov 2026~LLYTirzepatide Phase 3 Est. Readout (SURPASS-T1D-2)
  • Nov 2026~GSKDostarlimab Phase 2 Est. Readout
  • Nov 2026~GILDSacituzumab govitecan Phase 2 Est. Readout (SG-ESCC)
  • Nov 2026~ABBVABBV-932 Phase 2 Est. Readout
  • Nov 2026~BYSIPlinabulin Phase 2 Est. Readout
  • Nov 2026~BGNETislelizumab (BGB-A317) Phase 2 Est. Readout
  • Nov 2026~ALKSALKS 2680 Phase 2 Est. Readout (Vibrance-3)
  • Nov 2026~SVAexperimental vaccine Phase 3 Est. Readout
  • Nov 2026~AZNDurvalumab Phase 2 Est. Readout
  • Nov 2026~LLYLY3938577 Phase 2 Est. Readout
  • Nov 2026~BNTXRO7198457 intravenous (IV) Phase 2 Est. Readout
  • Nov 2026~TNXPCyclobenzaprine HCl Phase 2 Est. Readout (OASIS)
  • Nov 2026~SKBBYSKB264 Phase 3 Est. Readout
  • Nov 2026~PCRXEnekinragene Inzadenovec (PCRX-201) Phase 2 Est. Readout
  • Nov 2026~IGCIGC-AD1-Active Phase 2 Est. Readout
  • Nov 2026~TXMDABT-101 Phase 2 Est. Readout
  • Nov 2026~REGNREGN2810 Phase 2 Est. Readout
  • Nov 2026~ATOS(Z)-endoxifen Phase 2 Est. Readout (EVANGELINE)
  • Nov 2026~JHPCYTACE with adebrelimab and bevacizumab Phase 2 Est. Readout
  • Nov 2026~ICLRBXQ-350 Phase 2 Est. Readout (ASIST)
  • Nov 2026~CAMX.STCAM2029 Phase 3 Est. Readout (SORENTO)
  • Nov 2026~NAMSObicetrapib Phase 3 Est. Readout (PREVAIL)
  • Nov 2026~NAMSobicetrapib + obicetrapib/evolocumab Phase 2 Est. Readout (VINCENT)
  • Nov 2026~SNYIsatuximab Phase 2 Est. Readout (UltraFrailMM)
  • Nov 2026~ARGXEmpasiprubart IV Phase 2 Est. Readout (empacific)
  • Nov 2026~ONCSonrotoclax Phase 2 Est. Readout
  • Nov 2026~KYKOYMogamulizumab Phase 2 Est. Readout
  • Nov 2026~VIRTobevibart Phase 2 Est. Readout
  • Nov 2026~KPRXKIO-104 Phase 2 Est. Readout (KLARITY-1)
  • Nov 2026~IMUXIMU-838 tablets Phase 3 Est. Readout (ENSURE-1)
  • Nov 2026~INCYRuxolitinib Phase 2 Est. Readout

Week 4Nov 16 - Nov 22(38 catalysts)

MRKPDUFA
Past

FDA PDUFA Date ENFLONSIA (clesrovimab) (standard)

ClesrovimabPhase 3

Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under 2 years of age at increased risk for severe RSV disease through their second RSV season

Nov 16
✓PositiveSEC
SVRAPDUFA
5d

FDA PDUFA Date Molgramostim (MOLBREEVI)

MolgramostimPhase 3

Autoimmune pulmonary alveolar proteinosis

Nov 22
00%
Source
Molgramostim FDA decision page →
CAPRPDUFA
5d

FDA PDUFA Date Deramiocel

Deramiocel (CAP-1002)Phase 3

Duchenne muscular dystrophy (upper limb function)

Nov 22
00%
Source
Deramiocel (CAP-1002) FDA decision page →
  • Nov 16IMDXIMDX — Stock Offering (424B5)
  • Nov 16JNJAcquisition — Ollin Biosciences ($3.3B)
  • Nov 16DRTSData Readout - Alpha DaRT
  • Nov 16LLYAcquisition — Calytrix Bio
  • Nov 2026~OTSKFDelamanid (DLM) Phase 3 Est. Readout (PHOENIx MDR-TB)
  • Nov 16OKYOConference Presentation - urcosimod
  • Nov 16PTCTConference Presentation
  • Nov 16BIOA-B.STConference Presentation - Leqembi
  • Nov 16TTRXTTRX — Stock Offering (424B5)
  • Nov 16GHStock Offering — $500.0 million (plus up to $50.0 million option)
  • Nov 16VREOFVREOF M&A / Acquisition
  • Nov 16DAVIAcquisition — Davion Healthcare Corp. ($10M)
  • Nov 16MDCXMDCX — Stock Offering (424B5)
  • Nov 16AAPGConference Presentation - APG-5918
  • Nov 16KALAOther
  • Nov 16CLGNConference Presentation
  • Nov 16ENLVStock Offering — $7.5 million (plus up to ~$9.0 million from warrant exercise)
  • Nov 17LKFTConference — gamgertamig
  • Nov 17NBIXConference Presentation
  • Nov 2026~AZNAZD0901 Phase 2 Est. Readout
  • Nov 17VTRSAcquisition — Pacira BioSciences, Inc.
  • Nov 17ICLRConference Presentation
  • Nov 17NVAXConference Presentation
  • Nov 17ABCLConference Presentation
  • Nov 17JAZZConference Presentation
  • Nov 17PULMAcquisition — Eos SENOLYTIX
  • Nov 2026~DSGNALECENSA - alectinib hydrochloride capsule Phase 3 Est. Readout (Drugs-SNPs)
  • Nov 18TLSAConference Presentation - intranasal foralumab
  • Nov 19ICCMOther
  • Nov 2026~RHHBYRO7269162 Phase 2 Est. Readout
  • Nov 19MDXHOther
  • Nov 20PPBTConference Presentation - IM1240
  • Nov 20RLYBOther
  • Nov 2026~INCYpovorcitinib Phase 2 Est. Readout
  • Nov 2026~SKYENimacimab injection Phase 2 Est. Readout (CBeyond)

Week 5Nov 23 - Nov 29(17 catalysts)

SNYPDUFA
2w

FDA PDUFA Date Venglustat

VenglustatPhase 3

Type 3 Gaucher disease

Nov 25
00%
Source
Venglustat FDA decision page →
GSKPDUFA
2w

FDA PDUFA Date neladalkib (NVL-655)

Neladalkib (NVL-655)Phase 3

TKI pre-treated advanced ALK-positive NSCLC

Nov 27
00%
Source
Neladalkib (NVL-655) FDA decision page →
RPRXPDUFA
2w

FDA PDUFA Date neladalkib (priority)

neladalkibNDA

non-small cell lung cancer (ALK-positive)

Nov 27
00%
SEC
neladalkib FDA decision page →
BBIOPDUFA
2w

FDA PDUFA Date BBP-418

BBP-418NDA

Limb-girdle muscular dystrophy type 2I/R9

Nov 27
00%
Source
BBP-418 FDA decision page →
BBOTPDUFA
2w

FDA PDUFA Date BBP-418

BBP-418NDA
Nov 27
00%
Source
BBP-418 FDA decision page →
PYPDPDUFA
2w

FDA PDUFA Date D-PLEX100

D-PLEXPhase 3

Prevention of surgical site infections in abdominal colorectal surgery

Nov 28
00%
Source
D-PLEX FDA decision page →
  • Nov 2026~GSKdTpa Phase 3 Est. Readout
  • Nov 2026~GSKDostarlimab Phase 2 Est. Readout
  • Nov 24CLGNOther
  • Nov 2026~KRTXKarXT Phase 3 Est. Readout
  • Nov 2026~MKKGYAvelumab Phase 3 Est. Readout
  • Nov 2026~TECXTX000045- Dose A Phase 2 Est. Readout
  • Nov 2026~AZNAZD0754 Phase 2 Est. Readout (APOLLO)
  • Nov 25NNOXOther
  • Nov 2026~SNYrilzabrutinib Phase 3 Est. Readout
  • Nov 2026~SNYMeasles, combinations with mumps and rubella, live attenuated Phase 3 Est. Readout
  • Q4 2026~QPFERimegepant Phase 3 Est. Readout

Week 6Nov 30 - Dec 6(26 catalysts)

RHHBYPDUFA
2w

FDA PDUFA Date giredestrant (adjuvant)

GiredestrantPhase 3

Adjuvant ER-positive, HER2-negative stage I-III breast cancer

Nov 30
✓PositiveSource
ZLABPDUFA
2w

FDA PDUFA Date povetacicept (accelerated)

povetaciceptNDA

immunoglobulin A nephropathy (IgAN)

Nov 30
00%
SEC
povetacicept FDA decision page →
RHHBYNDA Filing
2w

NDA Filing — giredestrant

Nov 30
00%
Source
VRTXPDUFA
2w

FDA PDUFA Date povetacicept

PovetaciceptPhase 3

IgA nephropathy

Nov 30
00%
Source
Povetacicept FDA decision page →
RHHBYPDUFA
2w

FDA PDUFA Date Obinutuzumab (Gazyva)

Obinutuzumab/IntravenousPhase 2

Primary membranous nephropathy

Nov 30
✓PositiveSource
RHHBYRegulatory
2w

Regulatory — Gazyva/Gazyvaro

Nov 30
✓PositiveSource
PHIORegulatory
2w

Regulatory Decision - PH-762

Nov 30
00%
Source
  • Nov 2026~RHHBYAtezolizumab Phase 3 Est. Readout
  • Nov 2026~BIOAOral BGE-102 Phase 2 Est. Readout (QUELL-CV)
  • Nov 2026~TXMDRNK08954 Phase 2 Est. Readout
  • Nov 2026~AZNTremelimumab Phase 2 Est. Readout
  • Nov 2026~TXMDGS1191-0445 injection Phase 3 Est. Readout
  • Nov 2026~IMCRIMC-R117C Phase 2 Est. Readout
  • Nov 2026~AMGNAnvumetostat Phase 2 Est. Readout
  • Nov 2026~NTHIPerillyl alcohol Phase 2 Est. Readout
  • Nov 2026~AURAAU-011 Phase 2 Est. Readout
  • Nov 2026~TAKTAK-360 Phase 2 Est. Readout
  • Nov 2026~ARVNARV-806 Phase 2 Est. Readout
  • Nov 2026~VTRSMR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) Phase 2 Est. Readout
  • Nov 2026~SKBBYA166 Phase 3 Est. Readout
  • Nov 30DMACData Readout - DM199
  • Nov 2026~MRNAmRNA-3745 Phase 2 Est. Readout
  • Nov 2026~PHARLeniolisib Phase 3 Est. Readout
  • Nov 2026~IVBXFIBI363 Phase 2 Est. Readout
  • Nov 2026~BAVA.COMVA-BN (Quail) Phase 2 Est. Readout
  • Q4 2026~QIRLADexamethasone sodium phosphate Phase 3 Est. Readout

Get November Catalysts in Your Inbox

Subscribe to receive weekly digests of upcoming PDUFA dates and clinical trial results. Never miss an important FDA decision.

PDUFA dates November 2026: questions

How many FDA decisions (PDUFA dates) are in November 2026?
20 PDUFA dates fall in November 2026: 18 with a confirmed day, 6 already decided. Updated November 17, 2026.
What is the next FDA decision in November 2026?
Molgramostim from Savara Inc (SVRA), PDUFA target date Nov 22, for Autoimmune pulmonary alveolar proteinosis.
What is a PDUFA date?
The FDA's target date to complete its review of a new drug (NDA) or biologic (BLA) application. On or before it, the FDA approves the application, issues a complete response letter (CRL), or extends the review.

About PDUFA Dates in November 2026

This page tracks all FDA Prescription Drug User Fee Act (PDUFA) dates and biotech catalyst events scheduled for November 2026. PDUFA dates represent FDA's target action dates for reviewing new drug applications (NDAs) and biologics license applications (BLAs).

Biotech investors and traders closely monitor these dates as FDA decisions can significantly impact stock prices. Our calendar includes PDUFA dates, clinical trial results, advisory committee meetings, and other regulatory milestones.

Learn more about PDUFA dates or view the full biotech catalyst calendar.